SCHEMBL1200799

SCHEMBL1200799

NC(=O)CCOC(=O)c1cccc2nc(Nc3cc4ccccc4cn3)[nH]c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.35
NOTUM Q6P988 1/20 0.33
MAPT P10636 3/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
TP53 P04637 1/20 0.33
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
P2RY12 Q9H244 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
POLB P06746 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
CSNK1A1 P48729 1/20 0.31
CDK8 P49336 1/20 0.31
CDK5 Q00535 1/20 0.31
MAPK14 Q16539 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1201581 0.84 KMT2A (0.42) NOTUMMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1202450 0.81 DDX3X (0.42) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1202113 0.78 MAPK9 (0.44) NPC1RAB9ATP53SMN1; SMN2POLB
SCHEMBL1201690 0.76 KDR (0.43) MAPTSMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL1200580 0.76 MAPT (0.47) MAPTTP53SMN1; SMN2POLBMEN1
SCHEMBL1200797 0.75 MEN1 (0.42) MAPTRAB9APOLBKDM4EMEN1
SCHEMBL1201415 0.74 MEN1 (0.47) MAPTNPC1RAB9APOLBKDM4E
SCHEMBL1201780 0.73 KDR (0.45) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1201324 0.73 KMT2A (0.43) MAPTNPC1RAB9ATP53KDM4E
SCHEMBL1202140 0.73 HPGDS (0.40) NPC1RAB9ATP53SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065713-A1 Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2011-03-17 US disclosed
US-7893267-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2011-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065713-A1 Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors BACE1, BACE2, APP PARP1 1611/4885NOTUM 247/4885MAPT 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.